P01-019 – Anti-CCP antibodies are not associated with FMF
© Onur et al; licensee BioMed Central Ltd. 2013
Published: 8 November 2013
Familial Mediterranean Fever (FMF) is an autosomal recessive disease that is prevalent among eastern Mediterranean populations, mainly non-Ashkenazi Jews, Armenians, Turks, and Arabs. Arthritis seen in FMF patients is generally acute monoarthritis which predominantly affecting the lower limbs, and it occurs during attack periods and also is a common clinical manifestation in patients with FMF alike Rheumatoid arthritis (RA). Anti-cyclic citrullinated peptide (anti-CCP) antibodies testing is useful in the diagnosis of Rheumatoid arthritis with high specificity. The citrulline residues are essential part of the antigenic determinants recognized by the RA antibodies.
The aim of the study was to show the presence of anti-cyclic citrullinated peptide (anti-CCP) antibodies in child individuals diagnosed with Familial Mediterranean Fever (FMF) .
The study group was comprised of one hundred and twenty six patients diagnosed with FMF (female/male (n):66/60); and fifthy healthy control (female/male(n):25/25) . Clinical and laboratory assessments of the FMF patients were performed during attack-free periods. Erythrocyte sedimentation rate (ESR), serum C-reactive protein (CRP), fibrinogen and anti-CCP antibody levels were measured.
Anti-CCP results were negative in healthy controls and also in all FMF patients. There was not a significant difference in anti-CCP between the patient and the control groups. The patient individuals were divided into four groups according to genetic mutation analysis. The groups has been comprised as M694V/M694V(n=26), M694V/Other(n=38), Other/Other(n=46),Negative(n=16). No significant difference detected between four mutation groups and anti-CCP levels. Our study has shown moderate positive correlations between age (rs= 0.271; p= 0.0020), duration of illness (rs= 0.331; p<0.0001), colchicinetherapy (rs= 0.259; p= 0.004) and anti-CCP levels. Also poor positive correlations between fibrinogen and anti ccp levels was detected (rs= 0.192; p= 0.0330). Anti-CCP levels has not shown significance between patients with or without arthritis(p=0.148).
In conclusion, no published data in children establish anti-CCP values in patients with FMF compared with healthy controls. Our data show that anti-CCP antibodies are not associated with FMF. Anti-CCP does not have a priority for identifying FMF arthritis from the other inflammatory arthritis.
Disclosure of interest
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.